Christopher P Filson1, Jeffrey S Montgomery2, Stephen M Dailey2, Heather S Crossley2, Heidi Lentz3, Christopher T Tallman2, Chang He2, Alon Z Weizer4. 1. Division of Health Services Research, Department of Urology, University of Michigan Medical School, Ann Arbor, MI. 2. Division of Urologic Oncology, Department of Urology, University of Michigan Medical School, Ann Arbor, MI. 3. Division of Urologic Oncology, Department of Urology, University of Michigan Medical School, Ann Arbor, MI; Michigan State University, East Lansing, MI. 4. Division of Urologic Oncology, Department of Urology, University of Michigan Medical School, Ann Arbor, MI. Electronic address: aweizer@med.umich.edu.
Abstract
OBJECTIVES: To better understand the risk of short-term complications associated with perioperative intravesical mitomycin-C (MMC) therapy for patients undergoing endoscopic management of non-muscle invasive bladder cancer. METHODS AND MATERIALS: Using an institutional database of patients with bladder cancer, we performed a retrospective case-control study of patients receiving perioperative MMC after tumor resection (2008-2012). MMC cases were matched by clinical stage to controls receiving endoscopic resection alone. Demographic information, clinicopathologic details, and outcomes were compared between groups. Outcomes of interest included overall, genitourinary, and major complications. Chi-square tests and multivariable logistic regression were used to evaluate associations among patient characteristics, clinical factors, exposure to MMC, and outcomes of interest. RESULTS: One-hundred sixteen patients treated with MMC were matched to 116 controls. Patients receiving MMC were younger (P = 0.04) and more likely to have invasive disease (i.e. T1 or greater) (23% vs. 15%, P = 0.02). Complications were more frequent among patients who were treated with MMC (34.5% vs. 19.8%, Odds Ratio 2.89, 95% Confidence Interval 1.43-5.81). The most common complication among MMC patients that required medical management was dysuria (17%). Major complications were more common among MMC patients (5.2% vs. 0.9%), but this difference did not reach statistical significance (P = 0.11). CONCLUSIONS: Use of MMC is associated with a greater odds of complications compared with controls. Patients should be counseled regarding both the benefits and potential risks of perioperative intravesical MMC. Continued research is required to understand the safety implications associated with the use of perioperative, intravesical MMC.
OBJECTIVES: To better understand the risk of short-term complications associated with perioperative intravesical mitomycin-C (MMC) therapy for patients undergoing endoscopic management of non-muscle invasive bladder cancer. METHODS AND MATERIALS: Using an institutional database of patients with bladder cancer, we performed a retrospective case-control study of patients receiving perioperative MMC after tumor resection (2008-2012). MMC cases were matched by clinical stage to controls receiving endoscopic resection alone. Demographic information, clinicopathologic details, and outcomes were compared between groups. Outcomes of interest included overall, genitourinary, and major complications. Chi-square tests and multivariable logistic regression were used to evaluate associations among patient characteristics, clinical factors, exposure to MMC, and outcomes of interest. RESULTS: One-hundred sixteen patients treated with MMC were matched to 116 controls. Patients receiving MMC were younger (P = 0.04) and more likely to have invasive disease (i.e. T1 or greater) (23% vs. 15%, P = 0.02). Complications were more frequent among patients who were treated with MMC (34.5% vs. 19.8%, Odds Ratio 2.89, 95% Confidence Interval 1.43-5.81). The most common complication among MMCpatients that required medical management was dysuria (17%). Major complications were more common among MMCpatients (5.2% vs. 0.9%), but this difference did not reach statistical significance (P = 0.11). CONCLUSIONS: Use of MMC is associated with a greater odds of complications compared with controls. Patients should be counseled regarding both the benefits and potential risks of perioperative intravesical MMC. Continued research is required to understand the safety implications associated with the use of perioperative, intravesical MMC.
Authors: D A Tolley; T B Hargreave; P H Smith; J L Williams; K M Grigor; M K Parmar; L S Freedman; B M Uscinska Journal: Br Med J (Clin Res Ed) Date: 1988-06-25
Authors: Sven Oehlschläger; A Loessnitzer; Michael Froehner; Oliver W Hakenberg; Andreas Manseck; Manfred P Wirth Journal: Urol Int Date: 2003 Impact factor: 2.089
Authors: Frank N Burks; Alice B Liu; Ronald S Suh; Timothy G Schuster; Timothy Bradford; Don A Moylan; Peter M Knapp; Daniel S Murtagh; Rodney L Dunn; James E Montie; David C Miller Journal: J Urol Date: 2012-10-18 Impact factor: 7.450
Authors: Edward M Messing; Catherine M Tangen; Seth P Lerner; Deepak M Sahasrabudhe; Theresa M Koppie; David P Wood; Philip C Mack; Robert S Svatek; Christopher P Evans; Khaled S Hafez; Daniel J Culkin; Timothy C Brand; Lawrence I Karsh; Jeffrey M Holzbeierlein; Shandra S Wilson; Guan Wu; Melissa Plets; Nicholas J Vogelzang; Ian M Thompson Journal: JAMA Date: 2018-05-08 Impact factor: 56.272
Authors: Vanessa Bellat; Adam O Michel; Charlene Thomas; Tracy Stokol; Benjamin B Choi; Benedict Law Journal: Cancer Res Date: 2022-04-01 Impact factor: 12.701
Authors: Devon K Check; David S Aaronson; Matthew E Nielsen; Valerie S Lee; Isaac J Ergas; Janise M Roh; Lawrence H Kushi; Li Tang; Marilyn L Kwan Journal: Urology Date: 2018-10-23 Impact factor: 2.649
Authors: Charles C Peyton; Juan Chipollini; Mounsif Azizi; Ashish M Kamat; Scott M Gilbert; Phillippe E Spiess Journal: World J Urol Date: 2018-12-07 Impact factor: 3.661